Davis Aaron I. - 03 Sep 2024 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Other*
Issuer ticker: TNGX
Reported as of: 03 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2024, 21:01:38 UTC
Prior SEC filing: 13 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Davis Aaron I.

Key filing fact

Davis Aaron I. filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 05 Sep 2024.

Key facts

This page summarizes Davis Aaron I.'s Form 4 filing for Tango Therapeutics, Inc. (TNGX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Sep 2024, 21:01.

Change

Previous filing in this sequence was filed on 13 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Other

Transaction value: $0
Shares: +65,000
Change %
Price: $0.000000
Shares after: 65,000
Date: 03 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $10.93
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option, which was granted as compensation for consulting services, shall vest and become exercisable in 2 substantially equal installments, with 32,500 shares vesting as of 12/03/2024 and 32,500 shares vesting as of 03/03/2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC remarks

The Reporting Person may be deemed member of a group that beneficially owns more than 10% of the outstanding shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. As to any Reporting Person that is not a beneficial owner of more than 10% of the outstanding shares of Common Stock, this Form 4 shall not be deemed a concession that such person is subject to Section 16 of the Securities Exchange Act of 1934 with respect to the issuer.